Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00176605|
Recruitment Status : Completed
First Posted : September 15, 2005
Results First Posted : May 20, 2014
Last Update Posted : May 20, 2014
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: Etoposide Drug: Cyclophosphamide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Metronomic Dosing of Etoposide and Cyclophosphamide in Patients With Stage D0 Prostate Cancer.|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||October 2008|
|Actual Study Completion Date :||October 2008|
Experimental: Arm 1 (Etoposide + Cyclophosphamide)
Therapy will be divided into 4 cycles. Each cycle will be composed of 6 weeks of therapy. Total duration of therapy is 24 weeks. Administration of etoposide (50 mg po qd) and cyclophosphamide (50 mg po qd) will alternate in 21 day intervals. Starting with etoposide, patients will receive 21 days of therapy, upon completion of etoposide therapy patients will then receive 21 days of cyclophosphamide therapy. Therapy will continue in this alternating manner for 24 weeks. Week 1 of each cycle, begins with etoposide; Week 4 of each cycle, begins with cyclophosphamide.
50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
- PSA Response Rate [ Time Frame: 5 years ]The PSA response rate is the percentage of patients who have a PSA response. A PSA response will be considered a PSA decline of at least 50% must be confirmed by a second PSA value four or more weeks later. The reference PSA for these declines should be a PSA measured within 2 weeks prior to the initiation of therapy. Patients may not demonstrate clinical or radiographic evidence of disease progression during this period.
- Toxicities Related to Chronic Administration of Etoposide and Cyclophosphamide in Patients With Stage D0 Prostate Cancer. [ Time Frame: 5 years ]All patients who receive one dose of protocol therapy will be evaluable for toxicity. A total of 15 patients received at least one dose of protocol therapy. Adverse events are described in Adverse Event section.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00176605
|United States, New Jersey|
|Central Jersey Oncology Center|
|East Brunswick, New Jersey, United States, 08816|
|Robert Wood Johnson University Hospital/CINJ at Hamilton|
|Hamilton, New Jersey, United States, 08690|
|Morristown Memorial Hospital|
|Morristown, New Jersey, United States, 07962|
|Cancer Institute of New Jersey|
|New Brunswick, New Jersey, United States, 08901|
|Saint Peter's University Hospital|
|New Brunswick, New Jersey, United States, 08903|
|UMDNJ/Robert Wood Johnson Medical School|
|Newark, New Jersey, United States, 07103|
|Summit, New Jersey, United States, 070901|
|Principal Investigator:||Mark Stein, MD||Rutgers, The State University of New Jersey|